Cambridge, MA, September 26, 2007 --(PR.com
)-- Technologies are becoming available that will enable point-of-care assays that are rapid, accurate, and easy to use. The development of assays for applications in cardiac treatment, cancer, endocrine, immune disease, infectious disease will be highlighted, as well as the demand for generating reliable data and reducing costs associated with these tests. With the prospect of influenza and emerging pathogen outbreaks, resources are being addressed for this unmet medical need. Metrics for deciding which are the most promising prospects to meet this need will be discussed. At the event many of these topics will be discussed in the presentation by Scientia Advisors.
Harry Glorikian’s experience allows him to cover a broad range of areas within life sciences. His direct experience in sales, marketing, business development, and intellectual property combined with his technical and market knowledge provides unique and insightful perspectives. Harry has 15 years of experience in the life sciences developing and executing key strategic acquisitions and licensing arrangements targeting revenue growth channels. Harry currently leads Scientia, including the management of consulting teams, new business development, and intellectual capital development. His client engagements have involved comprehensive go-to-market plans in the areas of diagnostics, genomic, proteomics, cell biology, cellular therapy and consumables & services groups. His clients include both emerging innovators and global market leaders.